IMPRiND Project

Publishable summaries

IMPRiND produces annual publishable reports which describe the project achievements. They are public and and the latest can be downloaded by clicking on the links below.

IMPRiND Public Events

Below you will find information regarding public events organised by IMPRiND.

Scientific publications

Publications in peer-reviewed journals, conference proceedings, book chapters and books.
1.
Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-02014-y
2.
LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Acta Neuropathologica (2019). doi:10.1007/s00401-019-01995-0
3.
Propagation of α-Synuclein Strains within Human Reconstructed Neuronal Network.
Stem Cell Reports (2019). doi:10.1016/j.stemcr.2018.12.007
4.
Clustering of Tau fibrils impairs the synaptic composition of α3‐Na+/K+‐ATPase and AMPA receptors.
The EMBO Journal e99871 (2019). doi:10.15252/embj.201899871
5.
Pharmacological Transdifferentiation of Human Nasal Olfactory Stem Cells into Dopaminergic Neurons.
Stem Cells International (2019). https://www.hindawi.com/journals/sci/2019/2945435/.
6.
The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration.
Frontiers in Immunology 10, (2019). doi:10.3389/fimmu.2019.01139
7.
Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved.
Frontiers in Molecular Neuroscience 12, (2019). doi:10.3389/fnmol.2019.00107
8.
Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer’s and Pick’s disease.
bioRxiv 468892 (2018). doi:10.1101/468892
9.
Assessment of the efficacy of different procedures that remove and disassemble alpha-synuclein, tau and A-beta fibrils from laboratory material and surfaces.
Scientific Reports 8, 10788 (2018). doi:10.1038/s41598-018-28856-2
10.
Measurement of Tau Filament Fragmentation Provides Insights into Prion-like Spreading.
ACS Chemical Neuroscience 9, 1276-1282 (2018). doi:10.1021/acschemneuro.8b00094
11.
Tau Filaments and the Development of Positron Emission Tomography Tracers.
Frontiers in Neurology 9, (2018). doi:10.3389/fneur.2018.00070
12.
Structures of filaments from Pick’s disease reveal a novel tau protein fold.
Nature 561, 137-140 (2018). doi:10.1038/s41586-018-0454-y
13.
Tau filaments from multiple cases of sporadic and inherited Alzheimer’s disease adopt a common fold.
Acta Neuropathologica 136, 699-708 (2018). doi:10.1007/s00401-018-1914-z
14.
123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson’s disease cohort versus Parkinson’s disease: 123I-FP-CIT IMAGING IN A P.A53T PD COHORT.
Movement Disorders 33, 1734-1739 (2018). doi:10.1002/mds.27451
15.
Neurodegeneration and the ordered assembly of α-synuclein.
Cell and Tissue Research 373, 137-148 (2018). doi:10.1007/s00441-017-2706-9
16.
A Critical Assessment of Exosomes in the Pathogenesis and Stratification of Parkinson’s Disease.
Journal of Parkinson’s Disease 7, 569-576 (2017). doi:10.3233/JPD-171176
17.
Cryo-EM structures of tau filaments from Alzheimer’s disease.
Nature 547, 185-190 (2017). doi:10.1038/nature23002
18.
How is alpha-synuclein cleared from the cell?.
Journal of Neurochemistry doi:10.1111/jnc.14704

Project Flyer

The IMPRiND project flyer describes the project at a glance. It is mainly intended as a printed product but its electronic version is available for download.

This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.